Eye-Connect: Podcast Channel cover art

Eye-Connect: Podcast Channel

Eye-Connect: Podcast Channel

Written by: American Academy of Ophthalmology and Paradigm Medical Communications LLC
Listen for free

About this listen

 Welcome to the Eye-Connect Podcast Channel. This channel is provided by the American Academy of Ophthalmology and Paradigm Medical Communications, LLC. The goal of the Eye-Connect: Podcast Channel is to offer a variety of continuing education podcasts that will help support busy ophthalmology clinicians by providing focused updates on the latest data surrounding long-acting intravitreal anti-VEGF therapies for retinal vascular diseases, such as macular edema secondary to retinal vein occlusion (RVO) and diabetic macular edema (DME). The full Eye-Connect Learning Center, which features multiple individually accredited CE activities with patient and clinician resources, is for educational purposes only. Healthcare professionals are expected to employ their own knowledge and judgement during any discussion with, or treatment of, their patients.© 2026 American Academy of Ophthalmology except where noted. Content may not be reproduced in whole or part without the express written permission of the American Academy of Ophthalmology.
Episodes
  • Challenges in RVO Care

    Challenges in RVO Care
    Dec 1 2025

    Please CLICK HERE (https://www.eye-connect.org/rvo/1403-1/) to review the CME information and complete the pretest for this activity.

    Join host Dr Sridhar and guests Drs Ip and Bakri for a podcast highlighting the challenges in care of patients with macular edema secondary to retinal vein occlusion (RVO). With the American Academy of Ophthalmology RVO Preferred Practice Pattern as a guide, the faculty consider the current approach to treatment using anti-vascular endothelial growth factor (VEGF) agents and factors that may suggest a need for more intensive, long-term treatment. The anti-VEGF agents have been standard of care for over a decade; however, many patients need frequent injections to be effective. The anti-VEGF agents faricimab and aflibercept 8 mg have shown noninferior efficacy and greater durability in pivotal clinical trials at reducing patient treatment burden.

    When you are finished, please CLICK HERE to complete the posttest and evaluation.

    TRANSCRIPT

    REFERENCES

    Show More Show Less
    30 mins
No reviews yet